Patents Examined by Deborah Lambkin
  • Patent number: 5631210
    Abstract: Compounds of Formula I and their agriculturally suitable salts are disclosed which are useful for controlling undesired vegetation ##STR1## wherein Q is ##STR2## and R.sup.1 through R.sup.7, m, n, p and q are as defined in the disclosure.Also disclosed are compositions containing the compounds of Formula I and a method for controlling undesired vegetation which involves contacting the vegetation or its environment with an effective amount of a compound of Formula I.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: May 20, 1997
    Assignee: E. I. Du Pont de Nemours and Company
    Inventor: Chi-Ping Tseng
  • Patent number: 5631247
    Abstract: The present invention provides compounds and pharmaceutical compositions, optionally containing estrogen or progestin, and the use of such compounds, alone, or in combination with estrogen or progestin, for inhibiting the symptoms of postmenopausal symptoms, particularly osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer.The present invention further provides the use of the compounds of the present invention for inhibiting uterine fibroid disease and endometriosis in women, and aortal smooth muscle cell proliferation, particularly restenosis, in humans.
    Type: Grant
    Filed: July 15, 1996
    Date of Patent: May 20, 1997
    Assignee: Eli Lilly and Company
    Inventor: Jeffrey A. Dodge
  • Patent number: 5631277
    Abstract: Disclosed is (2-thione-1,3-dithiole 4,5-diyl) bis(thiocyanate), its preparation and its use as an antimicrobial and marine antifouling agent.
    Type: Grant
    Filed: July 10, 1996
    Date of Patent: May 20, 1997
    Assignee: The Dow Chemical Company
    Inventors: Duane R. Romer, Weishi W. Wu, Ravi B. Shankar, R. Garth Pews
  • Patent number: 5631263
    Abstract: A therapeutic method is provided to elevate a depressed mammalian autologous mixed lymphocyte response and to alleviate the diseases associated therewith by the administration of an effective amount of certain selective delta opioid receptor antagonists to a mammal such as a human patient in need of such treatment.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 20, 1997
    Assignees: Minneapolis Medical Research Foundation, Regents of the University of Minnesota
    Inventors: Philip S. Portoghese, Burt M. Sharp, Kristin M. Linner
  • Patent number: 5627215
    Abstract: The invention relates to compounds of formula (I), R.sub.1 and R.sub.2, each independently of the other, are selected from lower alkyl that is unsubstituted or substituted by one or more fluorine atoms which are not linked to the carbon atom of R.sub.1 or R.sub.2 bonding the nitrogen; from lower alkenyl wherein the double bond does not originate from the carbon atom that is bonded to a nitrogen bonding R.sub.1 or R.sub.2 ; from lower alkynyl wherein the triple bond does not originate from the carbon atom that is bonded to a nitrogen bonding R.sub.1 or R.sub.2 ; from cycloalkyl; and from cycloalkyl-lower alkyl; with the proviso that not more than one of the two radicals R.sub.1 and R.sub.2 is methyl; or salts thereof. The mentioned compounds are pharmacologically active against disorders that are responsive to a recuction in intracellular polyamines, such as tumours or protozoal diseases.
    Type: Grant
    Filed: August 18, 1995
    Date of Patent: May 6, 1997
    Assignee: Ciba-Geigy Corporation
    Inventors: Jorg Frei, Jaroslav Stanek
  • Patent number: 5618950
    Abstract: A sulfone charge transport agent and a multilayered electrophotographic element in which at least one of said layers includes polymeric binder and the sulfone charge transport agent. The general structure of the charge transport agent is: ##STR1## R is alkyl or cycloalkyl having from 1 to about 10 carbons, or aryl or heteroaryl having a total of carbons and heteroatoms of from 6 to about 12. T is alkyl having from 1 to 4 carbons.
    Type: Grant
    Filed: September 27, 1995
    Date of Patent: April 8, 1997
    Assignee: Eastman Kodak Company
    Inventors: Michael R. Detty, John A. Sinicropi, J. Robin Cowdery-Corvan, Ralph H. Young
  • Patent number: 5614639
    Abstract: The present invention provides processes for preparing 2-substituted benzo[b]thiophene compounds, some of which are useful as intermediates for preparing pharmaceutically-active compounds and others which are useful, inter alia, for the treatment of osteoporosis in postmenopausal women.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: March 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: Kenneth L. Hauser, Alan D. Palkowitz, Daniel J. Sall, Kenneth J. Thrasher
  • Patent number: 5610319
    Abstract: The invention generally relates to compounds of the formula I, which are in equilibrium with their 4-hydroxy tautomers, and their pharmaceutically acceptable salts: ##STR1## where n is 0 to 2; A is S, CH.sub.2, O, NH or Se, and when n is 0, A is not CH.sub.2, and when n is 1, A is not CH.sub.2 or NH; X is a substituted or unsubstituted C.sub.1 -C.sub.3 alkyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl or amino, or sulfur or oxygen; Ar is a substituted or unsubstituted monocyclic carbocycle or heterocycle, or fused or nonfused polycyclic carbocycle or heterocycle; and R.sub.1 and R.sub.2 are hydrogen or a moiety that forms together with the attached CO.sub.2 a readily hydrolyzable ester group. These compounds and their salts are useful as inhibitors of GARFT or as antiproliferative agents. The invention also pertains to pharmaceutical compositions and methods employing such Compounds as GARFT inhibitors or antiproliferative agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: March 11, 1997
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Michael D. Varney, William H. Romines, Cynthia L. Palmer
  • Patent number: 5608080
    Abstract: The present invention provides a process for producing a 2-substituted benzo[b]thiophene, which is characterized by reacting a substituted or unsubstituted 2-halogenobenzaldehyde with sulfur and a compound represented by general formula (1)H.sub.i S.sub.j M.sub.k (1)(wherein M represents an alkali metal; i represents an integer of 0 or 1; j represents an integer of 1 or more; and k represents an integer of 1-2 with a proviso that i+k=2), or with a compound of general formula (1) wherein j is 2 or more, in the presence of an aprotic polar solvent, and then reacting the reaction mixture with a compound represented by general formula (2)XCH.sub.2 R (2)(wherein X represents a halogen atom; and R represents an acyl group, a substituted or unsubstituted alkoxycarbonyl group, a substituted or unsubstituted arylcarbonyl group or a cyano group) to give rise to intramolecular ring closure.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: March 4, 1997
    Assignee: Ihara Chemical Industry Co., Ltd.
    Inventors: Naoto Yazawa, Yoshinori Saito, Hidetaka Hiyoshi
  • Patent number: 5608081
    Abstract: Novel hydroxymethylthiophene derivatives and their medical use in treating or preventing inflammation and edema.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: March 4, 1997
    Assignee: Industrial Technology Research Institute
    Inventors: Ching-Te Chang, Chen-Tao Lee, Fueng-Lan Lin
  • Patent number: 5606076
    Abstract: The present invention is directed to a process for the synthesis of 2-arylbenzo[b]thiophenes.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: James A. Aikins, Tony Y. Zhang
  • Patent number: 5605916
    Abstract: There is provided a method of treatment of neurological disorders, such as epilepsy, stroke and cerebral ischaemia, which comprises the administration of a compound of Formula I: ##STR1## wherein, Ar.sub.1 and Ar.sub.2, which may be the same or different, independently represent phenyl or phenyl substituted by one or more of amino, nitro, halogen, hydroxy, C1 to 6 alkoxy, C1 to 6 alkyl or cyano;R.sub.1 represents hydrogen, C1 to 6 alkyl, C1 to 6 alkoxycarbonyl;R.sub.2 represents hydrogen or COCH.sub.2 NH.sub.2 ;R.sub.3 represents hydrogen or C1 to 6 alkyl;in addition, when R.sub.2 represents hydrogen either one or both of Ar.sub.1 and Ar.sub.2 may also represent 2-, 3- or 4-pyridinyl and R.sub.1 may also represent trihalomethyl;or a pharmaceutically acceptable salt thereof.Some of the compounds of formula I are novel, and these are also provided, together with pharmaceutical compositions containing the novel compounds.
    Type: Grant
    Filed: March 6, 1995
    Date of Patent: February 25, 1997
    Assignee: Astra AB
    Inventors: Ronald C. Griffith, James J. Napier
  • Patent number: 5606075
    Abstract: The present invention is directed to new processes for the synthesis of 2-aryl benzo[b]thiophenes.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: David W. Hoard, Wayne D. Luke
  • Patent number: 5606069
    Abstract: The invention is antiobesity/antidiabetes beta-3 agonists of the formula: ##STR1## wherein Ar, X, R.sub.2, R.sub.3, Y and n are as defined in the specification.
    Type: Grant
    Filed: May 23, 1995
    Date of Patent: February 25, 1997
    Assignee: American Cyanamid Company
    Inventors: Joseph W. Epstein, Gary H. Birnberg, Minu D. Dutia, Thomas H. Claus, Elwood E. Largis
  • Patent number: 5603963
    Abstract: A method of treating retroviral diseases such as AIDS in an infected host is provided. The method comprises administering a therapeutically effective amount of at least one (pseudo)halogen complex of gold(I) in a pharmaceutically acceptable carrier. The (pseudo)halogen complex in gold(I) can be chosen from the group consisting of:R--Au--[CN], R--Au--[SCN], and R--Au--[SeCN].R may be chosen from the group consisting of: phosphines (such as triethylphosphine); halogens (such as chlorine); and pseudohalogens (such as an additional cyano, thiocyanato or selenocyanato moiety). When R is an additional cyano moiety, the complex is termed a dicyanogold(I) complex, i.e., [Au(CN).sub.2 ].sup.-, and is preferably employed as an alkali, ammonium or alkaline earth salt. When R is another moiety, the complex may be either neutral or anionic in nature, and any anionic complexes are also preferably present as alkali, ammonium or alkaline earth salts.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: February 18, 1997
    Assignee: University of Cincinnati
    Inventors: Richard C. Elder, Katherine T. Elder
  • Patent number: 5602135
    Abstract: Compounds of Formula 1 ##STR1## wherein m is 1-4; R.sub.1 -R.sub.4 independently are hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, or I; R.sub.5 is hydrogen, lower alkyl of 1 to 6 carbons, Cl, Br, I, lower alkoxy or lower thioalkoxy of 1-6 carbons; R.sub.6 is hydrogen, lower alkyl, Cl, Br, I, OR.sub.11, SR.sub.11, OCOR.sub.11, SCOR.sub.11, NH2, NHR.sub.11, N(R.sub.11).sub.2, NHCOR.sub.11 OR NR.sub.11 --COR.sub.11 ; R.sub.20 is independently hydrogen or lower alkyl; Y is an aromatic group such as phenyl or naphthyl, or a heteroaryl group selected from a group consisting of pyridyl, thienyl, furyl, pyridazinyl, pyrimidinyl, pyrazinyl, thiazolyl and oxazolyl; A is (CH.sub.2).sub.n where n is 0-5, lower branched chain alkyl having 3-6 carbons, cycloalkyl having 3-6 carbons, alkenyl having 2-6 carbons and 1 or 2 double bonds, alkynyl having 2-6 carbons and 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COOR.sub.8, CONR.sub.9 R.sub.10, --CH.sub.2 OH, CH.sub.2 OR.sub.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 11, 1997
    Assignee: Allergan
    Inventor: Roshantha A. Chandraratna
  • Patent number: 5596106
    Abstract: This invention discloses methods of using certain aryl-benzo[b]thiophene and benzo[b]furan compounds to block or inhibit cannabinoid receptors in mammals. It also discloses novel compounds which are antagonists of the cannabinoid receptors and also discloses pharmaceutical formulations which contain the compounds as an active ingredient.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 21, 1997
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Kennan J. Fahey, Gary A. Koppel
  • Patent number: 5596014
    Abstract: A pharmaceutical composition containing a compound and an excipient, the compound having the formula: ##STR1## in which n is 2, 3 or 4; R is H, --CH(R.sup.1).cndot.OR.sup.2, --CH(O--Z).sub.2, or --COR.sup.3 ; R.sup.1 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, OH, C.sub.1-6 hydroxyalkyl, or COOH; R.sup.2 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, tetrahydropyranyl, phenyl, benzoyl, C.sub.1-6 acyl, tosyl, or --CO--Y--COOH; and R.sup.3 is H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, OH, C.sub.1-6 hydroxyalkyl, or COOH; wherein Z is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, or C.sub.1-6 acyl; and Y is C.sub.1-6 alkylidene, C.sub.2-6 alkenylidene, phenylene, or deleted; or an ester or a salt thereof.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: January 21, 1997
    Assignee: Industrial Technology Research Institute
    Inventors: Ching-Te Chang, Rong-Tsun Wu
  • Patent number: 5593987
    Abstract: A method of inhibiting breast disorders administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3 ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: January 14, 1997
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, James J. Sales
  • Patent number: 5591869
    Abstract: Methylene compounds are preferably prepared by reducing an aluminum halide complex of the formula ##STR1## in which R.sup.1 represents a C.sub.6 -C.sub.10 -aryl radical which is optionally substituted by 1 to 4 C.sub.1 -C.sub.4 -alkyl radicals, 1 to 4 fluorine, chlorine and/or bromine atoms, one C.sub.1 -C.sub.8 -alkoxy group and/or one acetoxy group, or represents a heteroaryl radical which is optionally substituted by one C.sub.1 -C.sub.4 -alkyl radical and/or one fluorine, chlorine or bromine atom and contains 5 to 10 C atoms and one O or S atom andR.sup.2 represents a C.sub.1 -C.sub.12 -alkyl radical which is optionally substituted by 1 to 5 fluorine, chlorine and/or bromine atoms, independently of R.sup.1 represents a radical as defined for R.sup.1 and, in the case where R.sup.1 =a C.sub.6 -C.sub.
    Type: Grant
    Filed: December 6, 1995
    Date of Patent: January 7, 1997
    Assignee: Bayer Aktiengesellschaft
    Inventors: Helmut Fiege, Ferdinand Hagedorn